Full Generic Medicine Info
Dosage/Direction for Use

Allergic conditions
Adult: 4 mg 4-6 hrly.
Child: 2-6 yr 1 mg 4-6 hrly; >6-12yr 2 mg 4-6 hrly; >12 yr Same as adult dose.
May be taken with or without food. May be taken w/ food or milk to reduce GI discomfort.
Pregnancy (3rd trimester).
Special Precautions
Patient w/ glaucoma, prostatic hyperplasia, genitourinary obstruction, asthma, chronic bronchitis, thyroid dysfunction, CV disease (e.g. HTN, ischaemic heart disease). Childn. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness and sedation, if affected, do not drive or operate machinery.
Adverse Reactions
Excitability (esp in childn), drowsiness, sedation, angina pectoris, chest tightness, circulatory shock, extrasystoles, hypotension, palpitation, increased BP, tachycardia, anxiety, ataxia, chills, confusion, euphoria, fatigue, headache, hysteria, insomnia, irritability, nervousness, neuritis, paraesthesia, restlessness, seizure, tension, vertigo, diaphoresis, photosensitivity, rash, urticaria, abdominal cramps, anorexia, constipation, diarrhoea, epigastric distress, heartburn, nausea, vomiting, xerostomia, dysuria, early menstruation, urinary retention, agranulocytosis, haemolytic anaemia, thrombocytopenia, tremor, weakness, diplopia, mydriasis, blurred vision, acute labyrinthitis, tinnitus, polyuria, dry nose or throat, nasal congestion, bronchial secretions, wheezing.
Drug Interactions
May enhance the sedative effects of CNS depressants (e.g. barbiturates, anxiolytics, hypnotics, opioid analgesics, antipsychotics). Additive antimuscarinic effects w/ other antimuscarinic drugs (e.g. atropine, TCAs, MAOIs). May mask the warning signs of damage caused by ototoxic drugs (e.g. aminoglycosides).
Food Interaction
May enhance the CNS depressant effects of alcohol.
Lab Interference
May cause false-positive result w/ urine detection of amphetamine/methamphetamine. May interfere w/ skin tests using allergen extracts.
Brompheniramine is an antihistamine w/ antimuscarinic and moderate sedative actions. It competes w/ histamine for H1-receptor sites on effector cells.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 2-4 hr.
Distribution: Widely distributed. Volume of distribution: Approx 12 L/kg. Plasma protein binding: 39-49%.
Metabolism: Undergoes N-dealkylation to form monodesmethylbrompheniramine and didesmethylbrompheniramine, and is metabolised to propionic acid derivative.
Excretion: Via urine (approx 40%, as unchanged drug and metabolites) and faeces (approx 2%). Elimination half-life: Approx 25 hr.
Oral: Store between 15-30°C. Protect from light.
CIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AB01 - brompheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on brompheniramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in